行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

2.740
+0.040
+1.48%
交易中 14:39 05/24 EDT
开盘
2.680
昨收
2.700
最高
2.740
最低
2.660
成交量
3.92万
成交额
6.46万
52周最高
5.44
52周最低
2.020
市值
2.34亿
市盈率(TTM)
-1.2010
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解IMMP最新的财务预测,通过IMMP每股收益,每股净资产,每股现金流等数据分析Immutep近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测IMMP价格均价为8.55,最高价位9.13,最低价为8.11。
最高9.13
均价8.55
最低8.11
现价2.740
EPS
实际EPS
预期EPS
-0.22-0.17-0.11-0.06
Q1 2021
Q2 2021
机构持股
总机构数: 28
机构持股: 570.37万
持股比例: 6.68%
总股本: 8,541.23万
类型机构数股数
增持
8
24.29万
建仓
2
4.11万
减持
6
13.81万
平仓
3
2.86万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.05%
制药与医学研究
+0.15%
高管信息
Non-Executive Chairman/Independent Director
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman/Independent Director
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Secretary
Indira Naidu
Non-Executive Director
Lucy Turnbull
暂无数据
暂无数据
IMMP 简况
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMP股票基本功能。